Information Provided By:
Fly News Breaks for March 24, 2017
FPRX
Mar 24, 2017 | 06:38 EDT
Cowen analyst Chris Shibutani initiated Five Prime (FPRX) with an Outperform saying its proprietary IO platform is underappreciated by investors and has multiple clinical readouts in 2017 provide catalysts to drive value generation. The analyst said Five Prime's $1.8B out-licensing partnership deal with Bristol Myers (BMY) for Cabiralizumab in 2015 provides validation in supporting its platform.
News For FPRX From the Last 2 Days
There are no results for your query FPRX
I agree to the thefly.com's disclaimer & terms of use
About Privacy Terms of Use

© 1996-2018 TheStreet, Inc., 14 Wall Street, 15th Fl, NY, NY 10005

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.